Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population |
| |
| Authors: | Giovanni Maconi Cristina Bosetti Alberta De Monti Ray Kiran Boyapati Edward Shelton Nicole Piazza Anna Maria Carvalhas Gabrielli Marco Vincenzo Lenti Cristina Bezzio Chiara Ricci Salvatore Greco Samanta Romeo Francesco Giangregorio Daniele Gridavilla Fabio Tagliani Alessandro Massari Luca Pastorelli Antonio Di Sabatino Sandro Ardizzone |
| |
| Institution: | 1. Gastroenterology Unit, ASST Fatebenefratelli Sacco, Department of Biomedical and Clinical Sciences “L.Sacco” University of Milan, Italy;2. Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy;3. Department of Gastroenterology, Monash Health. Faculty of Medicine, Nursing & Health Sciences, Monash University, Clayton, Victoria, Australia;4. Gastroenterology Unit, IRCCS Policlinico San Donato, San Donato Milanese, Italy;5. Department of Internal Medicine, Fondazione IRCCS Policlinico San Matteo, Università degli Studi di Pavia, Pavia, Lombardia, Italy;6. Gastroenterology Unit, Rho Hospital, Rho (MI), ASST Rhodense, Garbagnate Milanese, Italy;7. Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy;8. Papa Giovanni XXIII Hospital, Gastroenterology and Digestive Endoscopy Units, Bergamo, Italy;9. Department of Gastroenterology and Endoscopy, Maggiore Hospital, ASST Crema, Crema, Italy;10. Internal Medicine and Gastroenterology, Codogno Hospital, Italy;11. I Division of Infectious Diseases, ASST Fatebenefratelli-Sacco, L. Sacco Hospital, Milan, Italy;12. III Division of Infectious Diseases, ASST Fatebenefratelli-Sacco, Department of Biomedical and Clinical Sciences, University of Milan, Italy;13. Department of Biomedical Sciences for Health, University of Milan, Milan, Italy;14. Division of Gastroenterology, ASST Spedali Civili, Brescia, Italy |
| |
| Abstract: | BackgroundIt is unclear whether patients with inflammatory bowel disease (IBD) are at increased risk of COVID-19.ObjectivesThis observational study compared the prevalence of COVID-19 symptoms, diagnosis and hospitalization in IBD patients with a control population with non-inflammatory bowel disorders.MethodsThis multicentre study, included 2733 outpatients (1397 IBD patients and 1336 controls), from eight major gastrointestinal centres in Lombardy, Italy. Patients were invited to complete a web-based questionnaire regarding demographic, historical and clinical features over the previous 6 weeks. The prevalence of COVID-19 symptoms, diagnosis and hospitalization for COVID-19 was assessed.Results1810 patients (64%) responded to the questionnaire (941 IBD patients and 869 controls). IBD patients were significantly younger and of male sex than controls. NSAID use and smoking were more frequent in controls. IBD patients were more likely treated with vitamin-D and vaccinated for influenza. Highly probable COVID-19 on the basis of symptoms and signs was less frequent in the IBD group (3.8% vs 6.3%; OR:0.45, 95%CI:0.28–0.75). IBD patients had a lower rate of nasopharyngeal swab-PCR confirmed diagnosis (0.2% vs 1.2%; OR:0.14, 95%CI:0.03–0.67). There was no difference in hospitalization between the groups (0.1% vs 0.6%; OR:0.14, 95%CI:0.02–1.17).ConclusionIBD patients do not have an increased risk of COVID-19 specific symptoms or more severe disease compared with a control group of gastroenterology patients. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
